A multicenter, phase II, double blind, randomized, parallel group, placebo-controlled study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure.
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2014
At a glance
- Drugs Serelaxin (Primary)
- Indications Acute heart failure
- Focus Biomarker; Pharmacodynamics
- Sponsors Novartis; Novartis Pharma A.G.
- 18 Nov 2013 Results published in the European Heart Journal.
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Oct 2012 Planned end date changed from 1 Oct 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History